SIRT2 promotes murine melanoma progression through natural killer cell inhibition

Abstract SIRT2, an NAD+-dependent histone deacetylase, has been shown to play a pivotal role in various physiological processes, however, its role in cancer is currently controversial. In recent years, SIRT2 has been described as both a tumor suppressor and oncogene with divergent expression and fun...

Full description

Bibliographic Details
Main Authors: Manchao Zhang, Scarlett Acklin, John Gillenwater, Wuying Du, Mousumi Patra, Hao Yu, Bo Xu, Jianhua Yu, Fen Xia
Format: Article
Language:English
Published: Nature Portfolio 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-92445-z
_version_ 1818839233292402688
author Manchao Zhang
Scarlett Acklin
John Gillenwater
Wuying Du
Mousumi Patra
Hao Yu
Bo Xu
Jianhua Yu
Fen Xia
author_facet Manchao Zhang
Scarlett Acklin
John Gillenwater
Wuying Du
Mousumi Patra
Hao Yu
Bo Xu
Jianhua Yu
Fen Xia
author_sort Manchao Zhang
collection DOAJ
description Abstract SIRT2, an NAD+-dependent histone deacetylase, has been shown to play a pivotal role in various physiological processes, however, its role in cancer is currently controversial. In recent years, SIRT2 has been described as both a tumor suppressor and oncogene with divergent expression and function in various malignancies. Using murine allograft melanoma models, our results suggest increased systemic expression of SIRT2 promotes tumor progression. In this study, SIRT2-overexpressing mice exhibited enhanced tumor growth and larger tumor volumes compared to their wild-type littermates. Mechanistically, systemic overexpression of SIRT2 reduces the number of tumor-infiltrating natural killer (NK) cells and suppresses NK cell function and proliferation within the tumor microenvironment (TME). Furthermore, despite the enhancing effect of NK cell depletion on tumor volume and growth rate in wild-type littermate mice, this effect was diminished in SIRT2-overexpressing mice. Lastly, pharmacological inhibition of SIRT2 increases NK cell tumor infiltration and suppresses allograft melanoma tumor growth. The findings of this study identify a dynamic functional interaction between systemic SIRT2 and NK cell activity, which controls melanoma tumor progression. Given the recent renewed interest in NK-cell-mediated immunotherapy response, SIRT2 could present a new opportunity to mediate immunotherapy response and resistance.
first_indexed 2024-12-19T03:51:02Z
format Article
id doaj.art-e610561f6fb24f419028b523a030e68e
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-12-19T03:51:02Z
publishDate 2021-06-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-e610561f6fb24f419028b523a030e68e2022-12-21T20:37:00ZengNature PortfolioScientific Reports2045-23222021-06-0111111310.1038/s41598-021-92445-zSIRT2 promotes murine melanoma progression through natural killer cell inhibitionManchao Zhang0Scarlett Acklin1John Gillenwater2Wuying Du3Mousumi Patra4Hao Yu5Bo Xu6Jianhua Yu7Fen Xia8Department of Radiation Oncology, University of Arkansas for Medical SciencesDepartment of Radiation Oncology, University of Arkansas for Medical SciencesDepartment of Radiation Oncology, University of Arkansas for Medical SciencesDepartment of Radiation Oncology, University of Arkansas for Medical SciencesDepartment of Radiation Oncology, University of Arkansas for Medical SciencesDepartment of Radiation Oncology, University of Arkansas for Medical SciencesDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research InstituteDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research InstituteDepartment of Radiation Oncology, University of Arkansas for Medical SciencesAbstract SIRT2, an NAD+-dependent histone deacetylase, has been shown to play a pivotal role in various physiological processes, however, its role in cancer is currently controversial. In recent years, SIRT2 has been described as both a tumor suppressor and oncogene with divergent expression and function in various malignancies. Using murine allograft melanoma models, our results suggest increased systemic expression of SIRT2 promotes tumor progression. In this study, SIRT2-overexpressing mice exhibited enhanced tumor growth and larger tumor volumes compared to their wild-type littermates. Mechanistically, systemic overexpression of SIRT2 reduces the number of tumor-infiltrating natural killer (NK) cells and suppresses NK cell function and proliferation within the tumor microenvironment (TME). Furthermore, despite the enhancing effect of NK cell depletion on tumor volume and growth rate in wild-type littermate mice, this effect was diminished in SIRT2-overexpressing mice. Lastly, pharmacological inhibition of SIRT2 increases NK cell tumor infiltration and suppresses allograft melanoma tumor growth. The findings of this study identify a dynamic functional interaction between systemic SIRT2 and NK cell activity, which controls melanoma tumor progression. Given the recent renewed interest in NK-cell-mediated immunotherapy response, SIRT2 could present a new opportunity to mediate immunotherapy response and resistance.https://doi.org/10.1038/s41598-021-92445-z
spellingShingle Manchao Zhang
Scarlett Acklin
John Gillenwater
Wuying Du
Mousumi Patra
Hao Yu
Bo Xu
Jianhua Yu
Fen Xia
SIRT2 promotes murine melanoma progression through natural killer cell inhibition
Scientific Reports
title SIRT2 promotes murine melanoma progression through natural killer cell inhibition
title_full SIRT2 promotes murine melanoma progression through natural killer cell inhibition
title_fullStr SIRT2 promotes murine melanoma progression through natural killer cell inhibition
title_full_unstemmed SIRT2 promotes murine melanoma progression through natural killer cell inhibition
title_short SIRT2 promotes murine melanoma progression through natural killer cell inhibition
title_sort sirt2 promotes murine melanoma progression through natural killer cell inhibition
url https://doi.org/10.1038/s41598-021-92445-z
work_keys_str_mv AT manchaozhang sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT scarlettacklin sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT johngillenwater sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT wuyingdu sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT mousumipatra sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT haoyu sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT boxu sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT jianhuayu sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition
AT fenxia sirt2promotesmurinemelanomaprogressionthroughnaturalkillercellinhibition